SEC Adopts Rule Requiring Listing Standards for

New Post Public Reply Private Reply Replies (0) Message Board
MaxShockeR

SEC Adopts Rule Requiring Listing Standards for Compensation Committees and Compensation Advisers

FOR IMMEDIATE RELEASE

2012-115

Washington, D.C., June 20, 2012 — The Securities and Exchange Commission has approved a rule that directs national securities exchanges to adopt listing standards for public company boards of directors and compensation advisers.

The new rule, required by the Dodd-Frank Wall Street Reform and Consumer Protection Act, requires exchange listing standards to address:

  • The independence of the members on a compensation committee
  • The committee’s authority to retain compensation advisers
  • The committee’s consideration of the independence of any compensation advisers and
  • The committee’s responsibility for the appointment, compensation, and oversight of the work of any compensation adviser.

Once an exchange’s new listing standards are in effect, a listed company must meet the standards in order for its shares to continue trading on that exchange.

“This rule will help to enhance the board's decision-making process on executive compensation matters, particularly the selection, engagement and oversight of compensation advisers, and will provide more transparency with respect to conflicts of interest of consultants engaged by boards,” said SEC Chairman Mary L. Schapiro.

The SEC also amended its proxy disclosure rules to require new disclosures from companies about their use of compensation consultants and conflicts of interest.

The new rule and rule amendments will take effect 30 days after publication in the Federal Register. No later than 90 days after effectiveness, each exchange that lists equity securities must propose listing standards that comply with the new rule. The new listing standards must be approved by the Commission within one year of the new rule becoming effective.

# # #

FACT SHEET

Listing Standards for Compensation Committees and Compensation Advisers

Background

In 2010, Congress passed the Dodd-Frank Act. Section 952 of the Act addresses the issue of executive compensation by focusing on the compensation committees formed by corporate boards as well as the compensation advisers that these committees retain.

Section 952 requires the SEC to direct the exchanges to adopt certain “listing standards” relating to the independence of the members on a compensation committee, the committee’s authority to retain compensation advisers, and the committee’s responsibility for the appointment, compensation and work of any compensation adviser. Once an exchange’s new listing standards are in effect, a listed company must meet these standards in order for its shares to continue trading on that exchange.

In addition, the provision requires each company to disclose in its proxy material for an annual meeting of shareholders whether its board’s compensation committee retained or obtained the advice of a compensation consultant. The provision also requires a company to disclose whether the work of the compensation consultant has raised any conflict of interest and, if so, the nature of the conflict and how the conflict is being addressed.

Requirements of the Rules

Independence of Compensation Committee Members

Under new Rule 10C-1, the exchanges are required to adopt listing standards that require each member of a company’s compensation committee to be a member of the board of directors and to be independent. In developing a definition of independence, the exchanges will be required to consider relevant factors, including, but not limited to:

  • The source of compensation of a member of the board of directors, including any consulting, advisory or other compensatory fee paid by the company to such director, and
  • Whether a member of the board of directors of a company is affiliated with the company, a subsidiary of the company, or an affiliate of a subsidiary of the company.

Authority and Funding of the Compensation Committee

Rule 10C-1 requires the exchanges to adopt listing standards providing that the compensation committee of a listed company:

  • May, in its sole discretion, retain or obtain the advice of a compensation adviser
  • Is directly responsible for the appointment, compensation and oversight of compensation advisers, and
  • Must be appropriately funded by the listed company.

Compensation Adviser Selection

Rule 10C-1 also requires the exchanges to adopt listing standards providing that a compensation committee may select a compensation consultant, legal counsel or other adviser, other than in-house legal counsel, only after considering the following six independence factors:

  • Whether the compensation consulting company employing the compensation adviser is providing any other services to the company
  • How much the compensation consulting company who employs the compensation adviser has received in fees from the company, as a percentage of that person’s total revenue
  • What policies and procedures have been adopted by the compensation consulting company employing the compensation adviser to prevent conflicts of interest
  • Whether the compensation adviser has any business or personal relationship with a member of the compensation committee
  • Whether the compensation adviser owns any stock of the company, and
  • Whether the compensation adviser or the person employing the adviser has any business or personal relationship with an executive officer of the issuer.

The exchanges themselves may impose additional factors.

Oversight by Board Members Outside of a Committee

These listing standards, with limited exceptions, will also apply to members of a listed company’s board of directors who, in the absence of a board committee, oversee executive compensation matters on behalf of the board of directors.

Exemptions

Rule 10C-1 requires the exchanges to exempt the following four categories of companies from the compensation committee independence requirements:

  • Limited partnerships
  • Companies in bankruptcy proceedings
  • Open-end management investment companies registered under the Investment Company Act of 1940
  • Any foreign private issuer that discloses in its annual report the reasons that the foreign private issuer does not have an independent compensation committee.

Rule 10C-1 authorizes the exchanges to exempt a particular relationship from the independence requirements applicable to compensation committee members.

Rule 10C-1 also exempts controlled companies and smaller reporting companies from all of the requirements of the new compensation committee listing standards and authorizes the exchanges to exempt other categories of issuers. As with all listing standards, the exchanges would need to seek the approval of the SEC before adopting any exemptions.

Compensation Consultant Conflicts of Interest Disclosure

Exchange Act registrants subject to the federal proxy rules already are required to disclose information about their use of compensation consultants, including specific information about fees paid to consultants. Under the new amendments to the proxy disclosure rules, with respect to any compensation consultant that has played a role in determining or recommending the amount or form of executive and director compensation and whose work has raised any conflict of interest, companies will be required to disclose the nature of the conflict and how the conflict is being addressed.

Source http://www.sec.gov/news/press/2012/2012-115.htm


Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 61

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 144

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Air Sealing First: Boosting Home Comfort & Efficiency

Updated Category News Views 69

Everyone wants a cozy, energy-efficient home, right? Well, the first step to achieving that might just surprise you. Forget about shoving more insulation into the walls for a second; air sealing should be your starting line. That's the drum Insulation Expert Mike Mancuso is beating, and he's got a point worth considering before you touch another insulation panel. Cracking...

Continue Reading
ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 181

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading
Miranda Lambert Lights Up Red Kettle Campaign

Updated Category News Views 28

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 80

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 149

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 252

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 96

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 331

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading

Top 5 Most Recently Viewed Articles

Warner Bros. Discovery's Remarkable Stock Surge Explained

Updated Category News Views 309

Warner Bros. Discovery Experiences Impressive Stock Surge Warner Bros. Discovery Inc. (NASDAQ: WBD) has been making headlines recently, with its stock surging dramatically. Investors and market enthusiasts are keenly observing this upward trend, particularly following a substantial rally. Record-Breaking Rally The company achieved an incredible milestone with its largest...

Continue Reading
Stellantis Reports 20% Q3 Shipment Drop, Market Reactions

Updated Category News Views 98

Stellantis Faces Significant Q3 Shipment Decline Stellantis (EPA: STLAM) (NYSE: STLA) recently reported a 20% drop in global shipments for the third quarter, prompting a notable reaction in the markets. The decline has been attributed to several factors including strategic inventory reduction measures and delays in the release of new models. During this challenging...

Continue Reading
Stifel Affirms Buy Rating on Elanco Amid New Drug Approval

Updated Category News Views 70

Stifel Stands Firm on Elanco Animal Health Stifel, a prominent financial services firm, has recently reaffirmed its Buy rating for Elanco Animal Health (NYSE: ELAN) and has kept its price target at $20.00 per share. This decision comes on the heels of the U.S. Food and Drug Administration's (FDA) approval of Elanco's new drug, Zenrelia, which serves as a significant boost...

Continue Reading
ChargePoint and Siemens Drive EV Infrastructure Innovation

Updated Category News Views 94

ChargePoint and Siemens Lead the Charge in Clean Tech The clean tech revolution is moving at an impressive pace, particularly with the growth of electric vertical takeoff and landing (eVTOL) aircraft and electric vehicle (EV) infrastructure. Companies like ChargePoint Holdings Inc (NYSE: CHPT) and Siemens AG (OTCPK: SIEGY) are crucial in shaping a sustainable future for...

Continue Reading
Elevance Health Faces Class Action: Investors Seek Remedies

Updated Category News Views 259

Opportunities for Investors in Elevance Health Class Action The recent developments surrounding Elevance Health, Inc. have prompted considerable attention, particularly among investors who have experienced substantial financial losses. The law firm Robbins Geller Rudman & Dowd LLP has initiated a class action lawsuit targeting Elevance Health, which operates in the health...

Continue Reading